Abivax (ABVX) Long-Term Debt Issuances (2024 - 2026)

Abivax's (ABVX) quarterly Long-Term Debt Issuances came in at $1.3 million in Q1 2026, down 14.95% quarter-over-quarter from $1.5 million in Q4 2025.

Abivax (ABVX) Long-Term Debt Issuances (2024 - 2026) Analysis & Trends

Abivax's Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $1.3 million for Q1 2026.

  • On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $2.1 million, a 95.86% decrease from a year earlier, with the FY2025 full-year figure at $1.5 million, changed N/A from the prior year.
  • Long-Term Debt Issuances fell to $1.3 million in Q1 2026 per ABVX's latest filing, from $1.5 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $26.8 million in Q1 2024 and bottomed at -$658931.7 in Q3 2024.
  • The 3-year median for Long-Term Debt Issuances is $1.5 million (2025), against an average of $10.9 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Abivax 9.98 Bn 9.98 Bn - 1.29 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.29 Mn
Mar 31, 2026 1.29 Mn
Dec 31, 2025 1.52 Mn
Dec 31, 2025 1.52 Mn
Sep 30, 2024 -658,931.70
Sep 30, 2024 -658,931.70
Jun 30, 2024 25.76 Mn
Jun 30, 2024 25.76 Mn
Mar 31, 2024 26.75 Mn
Mar 31, 2024 26.75 Mn